Coates Laura C, Chandran Vinod, Ogdie Alexis, O'Sullivan Denis, Brooke Mel, Steinkoenig Ingrid, Mease Philip J, Ritchlin Christopher T, Kavanaugh Arthur
From the UK National Institute for Health Research (NIHR), Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PsAZZ Support Group, Bath, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cleveland Clinic, Cleveland, Ohio; Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; University of California at San Diego, San Diego, California, USA; Our Lady's Hospice and Care Services, Dublin, Ireland.
L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; V. Chandran, MBBS, MD, DM, Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital; A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; M. Brooke, Chair, PsAZZ Support Group; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, Clinical Professor, University of Washington School of Medicine; C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center; A. Kavanaugh, MD, Professor of Medicine, University of California at San Diego.
J Rheumatol. 2017 May;44(5):684-685. doi: 10.3899/jrheum.170144.
At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the treatment recommendations committee summarized its work and presented its plans for future updates. The committee announced a partnership between GRAPPA and Guideline Central to develop a pocket reference guide to the treatment recommendations. Because key new data appear regularly, the group discussed publishing periodic updates of the recommendations online through the GRAPPA Website as well as a goal of publishing another major update of the recommendations in 2020. The committee also announced that 2 GRAPPA members were awarded a grant from the International League of Associations for Rheumatology to look at potential adaptations of international treatment recommendations for resource-poor settings, particularly in South America and Africa.
在2016年银屑病和银屑病关节炎研究与评估小组（GRAPPA）年会上，治疗建议委员会总结了其工作，并介绍了未来更新计划。该委员会宣布GRAPPA与指南中心建立合作关系，以制定治疗建议袖珍参考指南。由于关键新数据定期出现，该小组讨论了通过GRAPPA网站在线定期发布建议更新内容，以及在2020年发布建议的另一重大更新版本的目标。委员会还宣布，两名GRAPPA成员获得了国际风湿病协会联盟的资助，以研究国际治疗建议在资源匮乏地区（特别是南美洲和非洲）的潜在适应性。
